OptimizeRx (OptimizeRx) Debt-to-Equity : 0.29 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Debt-to-Equity?

OptimizeRx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.22 Mil. OptimizeRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $34.60 Mil. OptimizeRx's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $126.55 Mil. OptimizeRx's debt to equity for the quarter that ended in Dec. 2023 was 0.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for OptimizeRx's Debt-to-Equity or its related term are showing as below:

OPRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.29
Current: 0.29

During the past 13 years, the highest Debt-to-Equity Ratio of OptimizeRx was 0.29. The lowest was 0.00. And the median was 0.01.

OPRX's Debt-to-Equity is ranked better than
60.15% of 547 companies
in the Healthcare Providers & Services industry
Industry Median: 0.46 vs OPRX: 0.29

OptimizeRx Debt-to-Equity Historical Data

The historical data trend for OptimizeRx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Debt-to-Equity Chart

OptimizeRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.29

OptimizeRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	0.29

Competitive Comparison of OptimizeRx's Debt-to-Equity

For the Health Information Services subindustry, OptimizeRx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptimizeRx's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where OptimizeRx's Debt-to-Equity falls into.

OptimizeRx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

OptimizeRx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.222	+	34.602)	/	126.553
	=	0.29

OptimizeRx's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.222	+	34.602)	/	126.553
	=	0.29

OptimizeRx (NAS:OPRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

OptimizeRx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

OptimizeRx (OptimizeRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Water Street, Suite 200, Rochester, MI, USA, 48307

Website

https://www.optimizerx.com

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Executives

Marion Odence-ford	officer: General Counsel and CCO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco	officer: Chief Commercial Officer	260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch	officer: Chief Product Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo	officer: Chief Executive Officer	600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro	officer: Chief Commercial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh	officer: COO and CFO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore	officer: President	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler	director, officer: SVP of Product & Strategy	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker	officer: Chief Financial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman	officer: Chief Technology Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson	director	200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas	director	38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022